相关实验视频
Updated: May 9, 2026

13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
14.0K
儿科中甲血球蛋白血症:一个复杂的诊断旅程
Inês Aires Martins1, Joana Carvalho Queirós2, Esmeralda Cleto3
1Pediatrics Department, Centro Hospitalar Universitário do Porto EPE Centro Materno-Infantil do Norte Dr Albino Aroso, Porto, Portugal inesairesmartins@gmail.com.
BMJ case reports
|February 14, 2025
概括
甲血球蛋白血症是一种血红铁氧化的情况,损害了氧气的输送. 这个案例突出了诊断这种罕见的疾病,细胞染色体b5还原酶缺乏症,在一个有异常症状的青少年.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
背景情况:
- 甲血球蛋白血症涉及血铁的氧化 (Fe2+到Fe3+),损害了氧气的运输.
- 原因包括药物暴露或遗传的细胞染色体b5减少酶缺乏.
- 诊断可能是具有挑战性的,特别是没有经典的蓝色病.
研究的目的:
- 在青少年中报告甲血球蛋白血症病例.
- 为了说明非典型呈现的诊断挑战.
- 强调识别罕见遗传病因的重要性.
主要方法:
- 临床病例的介绍.
- 评估SpO2水平和对氧气的反应.
- 对甲血球蛋白血的诊断工作.
主要成果:
- 一个青少年出现了持续的咳和低SpO2.
- 诊断出由于cytochrome b5减少酶缺乏症而导致的甲血球蛋白血症得到证实.
- 没有色症等经典症状.
结论:
- 甲血球蛋白血的非典型表现需要彻底的临床评估.
- 细胞染色体b5还原酶缺乏是无法解释的低氧化症的关键差异诊断.
- 提高对罕见病因的认识对于及时诊断和管理至关重要.
相关概念视频
Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

